Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Ibrutinib and Venetoclax Target Distinct Subpopulation of CLL Cells: Rationale for Drug Combination and Implication of Minimal Residual Disease Eradication

Y. Lynn Lynn Wang, MD PhD, Carrie Franzen, PhD, Shengchun Wang, MD PhD, Girish Venkataraman, MD MBBS, Lei Li, MS, Nifang Niu, PhD, Madina Sukhanova, PhD, Yifan Tu, MD PhD, Juehua Gao, MD PhD, Yi-Hua Chen, MD, Shuo Ma, MD PhD, Richard A. Larson, MD, Lu Pin, MD PhD

Blood (2019) 134 (Supplement_1): 475.

https://doi.org/10.1182/blood-2019-125396

Published: 2019

Journal Articles

TP53 Aberrations By FISH in CLL and Complex Karyotype at Transformation Predict for Worse Outcome in Diffuse Large B-Cell Lymphoma - Richter Transformation: A Single Institution Series of 75 DLBCL-RT Cases

Shiraz Fidai, MD, Madina Sukhanova, PhD, Brian C.-H. Chiu, PhD, Y. Lynn Lynn Wang, MD PhD, Wendy Stock, MD, Peter A Riedell, MD, Sonali M. Smith, MD, Elizabeth Hyjek, MD, Girish Venkataraman, MD MBBS

Blood (2018) 132 (Supplement 1): 2984.

https://doi.org/10.1182/blood-2018-99-112242

Published: 2018

Journal Articles

XPO1 Inhibitor Selinexor Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma Via Nuclear Retention of IκB

Y. Lynn Wang, MD PhD, Mei Ming, PhD, Bingqing Xie, Madina Sukhanova, Weige Wang, MD, Sabah Kadri, PhD, Shruti Sharma, Jimmy Lee, Sharon Shacham, PhD MBA, Yosef Landesman, PhD, Natalia Maltsev, Pin Lu, PhD

Blood (2017) 130 (Supplement 1): 3837.

https://doi.org/10.1182/blood.V130.Suppl_1.3837.3837

Published: 2017

Journal Articles

PET-CT Invisible Diffuse Large B-Cell Lymphoma Features a Silent B-Cell Receptor Signaling

Dong Sheng, MD, Ting Li, MD, Xiangnan Jiang, MD, Weige Wang, MD, Y. Lynn Wang, MD PhD, Xiaoqiu Li

Blood (2017) 130 (Supplement 1): 2853.

https://doi.org/10.1182/blood.V130.Suppl_1.2853.2853

Published: 2017

Journal Articles

Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B Cell Malignancies: Results from a Phase I Dose Escalation Study

Gregory P. Coffey, PhD, Jiajia Feng, MD, Andreas Betz, PhD, Anjali Pandey, PhD, Matt Birrell, B.S., Janet M. Leeds, PhD, Kenneth Der, PhD, Sabah Kadri, PhD, Pin Lu, PhD, Jeremy Segal, PhD, Lynn Wang, MD PhD, Glenn Michelson, MD, John T Curnutte, MD PhD, Pamela B. Conley, PhD

Blood (2017) 130 (Supplement 1): 2782.

https://doi.org/10.1182/blood.V130.Suppl_1.2782.2782

Published: 2017

Journal Articles

Genetic or CD40L-Mediated Loss of Iκbα Is Associated with Resistance to the Dual SYK/JAK Inhibitor Cerdulatinib in DLBCL Cell Lines

Greg P Coffey, PhD, Jiajia Feng, MD, Sabah Kadri, PhD, Y. Lynn Wang, MD PhD, Pin Lu, PhD, Shruti Sharma, PhD, Jeremy Segal, PhD, Glenn Michelson, MD, Anjali Pandey, PhD, John T. Curnutte, MD PhD, Pamela B. Conley, PhD

Blood (2016) 128 (22): 2768.

https://doi.org/10.1182/blood.V128.22.2768.2768

Published: 2016

Journal Articles

Clonal Evolution Pattern of Leukemia Progression and Richter Transformation in Ibrutinib-Relapsed CLL Patients

Blood (2016) 128 (22): 3961.

https://doi.org/10.1182/blood.V128.22.3961.3961

Published: 2016

Journal Articles

Dual SYK/JAK Inhibition Overcomes Ibrutinib Resistance in Chronic Lymphocytic Leukemia

Yue Lynn Wang, MD PhD, Pin Lu, PhD, Greg P Coffey, PhD, Anjali Pandey, PhD, Ailin Guo, PhD MD

Blood (2016) 128 (22): 5377.

https://doi.org/10.1182/blood.V128.22.5377.5377

Published: 2016

Journal Articles

HSP90 Stabilizes B-Cell Receptor Kinases in a Multi-Client Interactome: PU-H71 Induces CLL Apoptosis in a Cytoprotective Microenvironment

Yue Lynn Wang, MD PhD, Pin Lu, PhD, Jimmy Lee, MD, Chao Jie Zhen, BS, Gabriela Chiosis, PhD, Ailin Guo, Ph DMD

Blood (2016) 128 (22): 5105.

https://doi.org/10.1182/blood.V128.22.5105.5105

Published: 2016

Journal Articles

An Accurate and Sensitive RT-qPCR Method That Reliably Detects BCR-ABL1 Beyond MR4.5

Nadia A. McDonald, B.Sc., MS, Brett E. Close, PhD, Pin Lu, PhD, Jeremy P. Segal, MD PhD, Yue Lynn Wang, MD PhD, Larissa V. Furtado, MD

Blood (2015) 126 (23): 5159.

https://doi.org/10.1182/blood.V126.23.5159.5159

Published: 2015

Journal Articles

An HSP90 Inhibitor, PU-H71, Antagonizes Stroma-Induced Pro-Survival Effects in CLL through Its Inhibition of Multi-Component B-Cell Receptor Signaling Pathway

Ailin Guo, PhDMD, Pin Lu, PhD, Chaojie Zhen, PhD, Gabriela Chiosis, PhD, Yue Lynn Wang, MD PhD

Blood (2015) 126 (23): 5289.

https://doi.org/10.1182/blood.V126.23.5289.5289

Published: 2015

Journal Articles

Higher BTK-Dependent Cell Proliferation in Unmutated Chronic Lymphocytic Leukemia Confers Increased Sensitivity to Ibrutinib

Ailin Guo, PhDMD, Pin Lu, PhD, Natalie Galanina, MD, Chadi Nabhan, MD, Sonali M. Smith, MD, Morton Coleman, MD, Yue Lynn Wang, MD PhD

Blood (2015) 126 (23): 5296.

https://doi.org/10.1182/blood.V126.23.5296.5296

Published: 2015

Journal Articles

SYK and STAT3 Are Active in Diffuse Large B-Cell Lymphoma: Activity of Cerdulatinib, a Dual SYK/JAK Inhibitor

Y. Lynn Wang, MD PhD, Jiao Ma, PhD, Wei Xing, PhD, Pin Lu, MD PhD, Karen Dresser, Ailin Guo, PhDMD, Anjali Pandey, PhD, Pamela B. Conley, PhD, Hongbo Yu, MD PhD, Greg Coffey, PhD

Blood (2014) 124 (21): 926.

https://doi.org/10.1182/blood.V124.21.926.926

Published: 2014

Journal Articles

A Novel Mutation In Bruton Tyrosine Kinase Confers Acquired Resistance To Ibrutinib (PCI-32765) In CLL

Richard R. Furman, MD, Shuhua Cheng, PhD, Pin Lu, MD, PhD, Menu Setty, Alexandar Perez, Ailin Guo, MD, PhD, Joelle Racchumi, BS, Jiao Ma, PhD, Morton Coleman, MD, Kabaleeswaran Venkataraman, PhD, Guozhou Xu, PhD, Wei Chen, PhD, Hao Wu, PhD, Betty Y. Chang, PhD, Christina Leslie, PhD, Y. Lynn Wang, MD, PhD

Blood (2013) 122 (21): 4914.

https://doi.org/10.1182/blood.V122.21.4914.4914

Published: 2013

Journal Articles

Dual SYK/JAK Inhibition Has a Broader Anti-Tumor Activity In Both ABC and GCB Types Of Diffuse Large B Cell Lymphoma

Jiao Ma, PhD, Greg Coffey, PhD, Pin Lu, MD, PhD, Shuhua Cheng, PhD, Ailin Guo, MD, PhD, Anjali Pandey, PhD, Y. Lynn Wang, MD, PhD

Blood (2013) 122 (21): 1833.

https://doi.org/10.1182/blood.V122.21.1833.1833

Published: 2013

Journal Articles

BTK Inhibition Targets in Vivo CLL Proliferation Through Its Effects On B-Cell Receptor Signaling Activity.

Y. Lynn Wang, MD, PhD, Shuhua Cheng, PhD, Jiao Ma, PhD, Ailin Guo, MD, PhD, Pin Lu, MD, PhD, John P. Leonard, MD, Morton Coleman, MD, Momo Liu, BS, Joseph J. Buggy, PhD, Richard R. Furman, MD

Blood (2012) 120 (21): 2903.

https://doi.org/10.1182/blood.V120.21.2903.2903

Published: 2012

Journal Articles

Busulfan Induces Hematologic and Molecular Responses in Polycythemia Vera (PV) Refractory to Multiple Drugs

Emil Tom Kuriakose, MD, Stefani Gjoni, BS, Y. Lynn Wang, MD, PhD, Amy Jones, PhD, Nicholas C.P. Cross, PhD, Richard T. Silver, MD

Blood (2012) 120 (21): 5068.

https://doi.org/10.1182/blood.V120.21.5068.5068

Published: 2012

Journal Articles

Chemosensitization of Diffuse Large B Cell Lymphoma by Demethylating Nucleoside Analogues

Thomas Clozel, MD, ShaoNing Yang, Ms, Matthias Kormaksson, PhD, Rebecca Elstrom, MD, Aparna Vasanthakumar, BSc, MSc, PhD, Sarah Brennan, PhD, Biljana Culjkovic, PhD, Michael Leser, Peter Martin, MD, Katherine LB Borden, PhD, Y. Lynn Wang, MD, PhD, Shuhua Cheng, PhD, Wayne Tam, MD, PhD, Rita Shaknovich, MD/PhD, Amy Chadburn, MD, Lucy Godley, MD, PhD, John P. Leonard, MD, Ari Melnick, MD, Leandro Cerchietti, MD

Blood (2011) 118 (21): 1617.

https://doi.org/10.1182/blood.V118.21.1617.1617

Published: 2011

Journal Articles

Activity of SYK and PLCγ2 Predict Apoptotic Response of Chronic Lymphocytic Leukemia Cells to SRC Tyrosine Kinase Inhibitor Dasatinib.

Y. Lynn Wang, MD, PhD, Zibo Song, Pin Lu, Richard R Furman, John P. Leonard, MD, Peter Martin, Lauren Tyrell, Francis Y. Lee, Daniel M. Knowles, Morton Coleman

Blood (2009) 114 (22): 1249.

https://doi.org/10.1182/blood.V114.22.1249.1249

Published: 2009

Journal Articles

Decrease in JAK2 V617F Allele Burden is Not a Prerequisite to Clinical Response in Patients with Polycythemia Vera (PV).

Richard T. Silver, MD, Katherine Vandris, Joshua J. Goldman, Fernando Adriano, Y. Lynn Wang, MD, PhD, Amy V. Jones, Paul J. Christos, PhD, N. C.P. Cross, PhD

Blood (2009) 114 (22): 1908.

https://doi.org/10.1182/blood.V114.22.1908.1908

Published: 2009

NARROW

Ibrutinib and Venetoclax Target Distinct Subpopulation of CLL Cells: Rationale for Drug Combination and Implication of Minimal Residual Disease Eradication

TP53 Aberrations By FISH in CLL and Complex Karyotype at Transformation Predict for Worse Outcome in Diffuse Large B-Cell Lymphoma - Richter Transformation: A Single Institution Series of 75 DLBCL-RT Cases

XPO1 Inhibitor Selinexor Overcomes Ibrutinib Resistance in Mantle Cell Lymphoma Via Nuclear Retention of IκB

PET-CT Invisible Diffuse Large B-Cell Lymphoma Features a Silent B-Cell Receptor Signaling

Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B Cell Malignancies: Results from a Phase I Dose Escalation Study

Genetic or CD40L-Mediated Loss of Iκbα Is Associated with Resistance to the Dual SYK/JAK Inhibitor Cerdulatinib in DLBCL Cell Lines

Clonal Evolution Pattern of Leukemia Progression and Richter Transformation in Ibrutinib-Relapsed CLL Patients

Dual SYK/JAK Inhibition Overcomes Ibrutinib Resistance in Chronic Lymphocytic Leukemia

HSP90 Stabilizes B-Cell Receptor Kinases in a Multi-Client Interactome: PU-H71 Induces CLL Apoptosis in a Cytoprotective Microenvironment

An Accurate and Sensitive RT-qPCR Method That Reliably Detects BCR-ABL1 Beyond MR4.5

An HSP90 Inhibitor, PU-H71, Antagonizes Stroma-Induced Pro-Survival Effects in CLL through Its Inhibition of Multi-Component B-Cell Receptor Signaling Pathway

Higher BTK-Dependent Cell Proliferation in Unmutated Chronic Lymphocytic Leukemia Confers Increased Sensitivity to Ibrutinib

SYK and STAT3 Are Active in Diffuse Large B-Cell Lymphoma: Activity of Cerdulatinib, a Dual SYK/JAK Inhibitor

A Novel Mutation In Bruton Tyrosine Kinase Confers Acquired Resistance To Ibrutinib (PCI-32765) In CLL

Dual SYK/JAK Inhibition Has a Broader Anti-Tumor Activity In Both ABC and GCB Types Of Diffuse Large B Cell Lymphoma

BTK Inhibition Targets in Vivo CLL Proliferation Through Its Effects On B-Cell Receptor Signaling Activity.

Busulfan Induces Hematologic and Molecular Responses in Polycythemia Vera (PV) Refractory to Multiple Drugs

Chemosensitization of Diffuse Large B Cell Lymphoma by Demethylating Nucleoside Analogues

Activity of SYK and PLCγ2 Predict Apoptotic Response of Chronic Lymphocytic Leukemia Cells to SRC Tyrosine Kinase Inhibitor Dasatinib.

Decrease in JAK2 V617F Allele Burden is Not a Prerequisite to Clinical Response in Patients with Polycythemia Vera (PV).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only